BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28521298)

  • 21. The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.
    Sanderson MP; Hofmann MH; Garin-Chesa P; Schweifer N; Wernitznig A; Fischer S; Jeschko A; Meyer R; Moll J; Pecina T; Arnhof H; Weyer-Czernilofsky U; Zahn SK; Adolf GR; Kraut N
    Mol Cancer Ther; 2017 Oct; 16(10):2223-2233. PubMed ID: 28729397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
    Ellis BC; Graham LD; Molloy PL
    Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor.
    Spicer LJ; Aad PY
    Biol Reprod; 2007 Jul; 77(1):18-27. PubMed ID: 17360960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.
    Oliva CR; Halloran B; Hjelmeland AB; Vazquez A; Bailey SM; Sarkaria JN; Griguer CE
    Cell Commun Signal; 2018 Sep; 16(1):61. PubMed ID: 30231881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
    Zhang M; Li Z; Liu X
    Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
    Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY
    Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
    Carugo A; Minelli R; Sapio L; Soeung M; Carbone F; Robinson FS; Tepper J; Chen Z; Lovisa S; Svelto M; Amin S; Srinivasan S; Del Poggetto E; Loponte S; Puca F; Dey P; Malouf GG; Su X; Li L; Lopez-Terrada D; Rakheja D; Lazar AJ; Netto GJ; Rao P; Sgambato A; Maitra A; Tripathi DN; Walker CL; Karam JA; Heffernan TP; Viale A; Roberts CWM; Msaouel P; Tannir NM; Draetta GF; Genovese G
    Cancer Cell; 2019 Feb; 35(2):204-220.e9. PubMed ID: 30753823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.
    Kuwahara Y; Iehara T; Ichise E; Katsumi Y; Ouchi K; Tsuchiya K; Miyachi M; Konishi E; Sasajima H; Nakamura S; Fumino S; Tajiri T; Johann PD; FrÜhwald MC; Yoshida T; Okuda T; Hosoi H
    Anticancer Res; 2020 Nov; 40(11):6159-6170. PubMed ID: 33109553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.
    Kuwahara Y; Mora-Blanco EL; Banine F; Rogers AB; Fletcher C; Sherman LS; Roberts CW; Weissman BE
    Int J Cancer; 2013 Jun; 132(12):2767-77. PubMed ID: 23197309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression.
    Kohashi K; Nakatsura T; Kinoshita Y; Yamamoto H; Yamada Y; Tajiri T; Taguchi T; Iwamoto Y; Oda Y
    Hum Pathol; 2013 Apr; 44(4):526-33. PubMed ID: 23084579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation.
    Tian D; Mitchell I; Kreeger PK
    BMC Syst Biol; 2016 Feb; 10():15. PubMed ID: 26861122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-Akt expression distinguishes two types of malignant rhabdoid tumors.
    Charboneau A; Chai J; Jordan J; Funkhouser W; Judkins A; Biegel J; Weissman B
    J Cell Physiol; 2006 Nov; 209(2):422-7. PubMed ID: 16897758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.
    Rikhof B; van der Graaf WT; Suurmeijer AJ; van Doorn J; Meersma GJ; Groenen PJ; Schuuring EM; Meijer C; de Jong S
    Am J Pathol; 2012 Jul; 181(1):303-12. PubMed ID: 22658485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II.
    Duplomb L; Chaigne-Delalande B; Vusio P; Raher S; Jacques Y; Godard A; Blanchard F
    Endocrinology; 2003 Dec; 144(12):5381-9. PubMed ID: 12959977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?
    Renard C; Pissaloux D; Decouvelaere AV; Bourdeaut F; Ranchère D
    Cancer Genet; 2014 Sep; 207(9):384-9. PubMed ID: 25053104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
    Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
    J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IGF-binding proteins 3 and 4 are regulators of sprouting angiogenesis.
    Dallinga MG; Habani YI; Kayser RP; Van Noorden CJF; Klaassen I; Schlingemann RO
    Mol Biol Rep; 2020 Apr; 47(4):2561-2572. PubMed ID: 32133604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.